ResearcherIowa State UniversityActive in the last 2 years
Balaji Narasimhan
Matched on ORCID iD 0000-0002-7955-5353; OpenAlex author ID A5107299854; NIH RePORTER profile ID 7715264. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 15
2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper, 1 grant · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 6
- A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. Last author DOI 10.1016/j.actbio.2026.04.026↗
- Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1007/s40883-025-00394-0↗
- Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. Co-author DOI 10.1016/j.isci.2025.114088↗
- Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Co-author DOI 10.7150/thno.64805↗
- Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. Last author DOI 10.1002/jbm.a.37080↗
- Emerging trends in the immunotherapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.12.012↗
Grants 1
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Surinder K. Batra · 6 shared papers, 2018–2026 · strength 1.05
- Paper Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. DOI 10.1016/j.isci.2025.114088↗
- Paper A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. DOI 10.1016/j.actbio.2026.04.026↗
- Paper Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1007/s40883-025-00394-0↗
- Maneesh Jain · 4 shared papers, 1 shared grant, 2018–2026 · strength 1.01
- Grant Nanovaccine platforms to combat pancreatic cancer U01CA213862↗
- Paper A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. DOI 10.1016/j.actbio.2026.04.026↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Aliasger K Salem · 2 shared papers, 1 shared grant, 2021–2026 · strength 0.81
- Grant Nanovaccine platforms to combat pancreatic cancer U01CA213862↗
- Paper A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. DOI 10.1016/j.actbio.2026.04.026↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Brianna M. White · 3 shared papers, 2022–2025 · strength 0.62
- Paper Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. DOI 10.1016/j.isci.2025.114088↗
- Paper Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1007/s40883-025-00394-0↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Shailendra Kumar Gautam · 4 shared papers, 2018–2026 · strength 0.56
- Paper A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. DOI 10.1016/j.actbio.2026.04.026↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Paper Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. DOI 10.1002/jbm.a.37080↗
- Joyce C. Solheim · 4 shared papers, 2018–2026 · strength 0.56
- Paper A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. DOI 10.1016/j.actbio.2026.04.026↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Paper Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. DOI 10.1002/jbm.a.37080↗
- Luman Liu · 3 shared papers, 2021–2026 · strength 0.49
- Paper A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. DOI 10.1016/j.actbio.2026.04.026↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Paper Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. DOI 10.1002/jbm.a.37080↗
- Susheel Kumar Nethi · 2 shared papers, 2025 · strength 0.49
- Venugopal Gunda · 2 shared papers, 2025 · strength 0.49
- Nagabhishek Sirpu Natesh · 2 shared papers, 2025 · strength 0.49
- Satyanarayana Rachagani · 2 shared papers, 2025 · strength 0.49
- Sushil Kumar K · 3 shared papers, 2018–2022 · strength 0.32
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Paper Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. DOI 10.1002/jbm.a.37080↗
- Paper Emerging trends in the immunotherapy of pancreatic cancer. DOI 10.1016/j.canlet.2017.12.012↗
- Kasturi Banerjee · 2 shared papers, 2018–2026 · strength 0.31
- Brittany J. Poelaert · 1 shared paper, 2018 · strength 0.07
- Rakesh Bhatia · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.